Volltextsuche nutzen
- versandkostenfrei ab € 30,–
- 6x in Wien und Salzburg
- 6 Mio. Bücher
- facultas
- Detailansicht
Leading Pharmaceutical Innovation
How to Win the Life Science Race
Taschenbuch
62,69€
inkl. gesetzl. MwSt.
Herstellung bei AnforderungVersandkostenfreibestellen in Österreich
Deutschland: € 10,00
EU & Schweiz: € 20,00
EU & Schweiz: € 20,00
In den Warenkorb
Click & Collect
Artikel online bestellen und in der Filiale abholen.
Derzeit in keiner facultas Filiale lagernd. Jetzt online bestellen!Artikel online bestellen und in der Filiale abholen.
Artikel in den Warenkorb legen, zur Kassa gehen und Wunschfiliale auswählen. Lieferung abholen und bequem vor Ort bezahlen.
Auf die Merkliste
Veröffentlicht 2019, von Oliver Gassmann, Alexander Schuhmacher, Max von Zedtwitz, Gerrit Reepmeyer bei Springer International Publishing
ISBN: 978-3-030-09782-0
Auflage: 3. Auflage
XV, 179 Seiten
XV, 179 p. 41 illus., 3 illus. in color.
23.5 cm x 15.5 cm
...
Beschreibung
This book investigates and highlights the most critical challenges the pharmaceutical industry faces in an increasingly competitive environment of inflationary R&D investments and tightening cost control pressures. The authors present three sources of pharmaceutical innovation: new management methods in the drug development pipeline; new technologies as enablers for cutting-edge R&D; and new forms of cooperation and internationalization, such as open innovation in the early phases of R&D. New models and methods are illustrated with cases from Europe, the US, and Asia. This third fully revised edition was expanded to reflect the latest updates in open and collaborative innovation, the greater strategic importance of venture capital and early-stage investments, and the new range of emerging technologies now being put to use in pharmaceutical innovation.
This book investigates and highlights the most critical challenges the pharmaceutical industry faces in an increasingly competitive environment of inflationary R&D investments and tightening cost control pressures. The authors present three sources of pharmaceutical innovation: new management methods in the drug development pipeline; new technologies as enablers for cutting-edge R&D; and new forms of cooperation and internationalization, such as open innovation in the early phases of R&D. New models and methods are illustrated with cases from Europe, the US, and Asia. This third fully revised edition was expanded to reflect the latest updates in open and collaborative innovation, the greater strategic importance of venture capital and early-stage investments, and the new range of emerging technologies now being put to use in pharmaceutical innovation.